

Phase III Disease Modifying Alzheimer's Therapeutic LMTM – A Tau Protein Aggregation Inhibitor

Evidence of disease reversal/prevention over 18 months in early stage AD

Radically reduced disease progression by more than 80% over 50 weeks and 70% over 102 weeks in large Phase II trial (321 subjects).

A unique, advanced compound

- ▶ Disease modifying agent with radical changes over 50 weeks in Phase II efficacy trial.
- ▶ Clear Mode of Action – Inhibiting toxic tau protein aggregation and breaks up existing aggregates.
- ▶ Late stage – Years of competitive lead in the tau pathology category.
- ▶ IP protection of composition of matter until 2027 including derivatives, formulations and synthesis.
- ▶ Safety comparable to AChEI drugs.


AD Market Opportunity

- ▶ Massive unmet medical need: 36 million patients worldwide; 6.6m in the seven major markets (5.1m in the US to grow over 50% by 2031).
- ▶ Conservative estimate: \$11.9B in 2019.
- ▶ Currently only symptomatic therapies available.
- ▶ Exceptional market expectation for a true disease modifying therapy.
- ▶ LMTM Phase II trials showed indication of first and best in class disease modification in current industry pipeline with multiple blockbuster sales potential.

Tau Pathology Gaining Lead


- ▶ Due to a number of late stage failures in targeting β amyloid, including bapineuzumab for carriers of ApoE4 (i.e. ineffective in 40% of cases).
- ▶ Tau protein inhibition is increasingly recognised as a leading therapeutic approach of disease modification.

Phase II results over 50 weeks



SPECT Results

Reduced cerebral perfusion (shown in red) versus no disease progression in treated group after 20 weeks.



Diseased Control Group

Treated Group

TR **TauRx Pharmaceuticals**
Therapies and Diagnostics for Neurodegenerative Diseases

Partnering contact:

Dr Tibor Papp, Head of Corporate Advisory

PharmaVentures Ltd. | Florey House | Oxford Science Park | Oxford OX4 4GP | UK
tiber.papp@pharmaventures.com | +44 (0)7810 837 786



PharmaVentures
Experts in deals and alliances